{"disease":{"id":"nf2","name":"nf2"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05228015","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT03672838","title":"A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)","phase":"NA","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT06834438","title":"Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}